Keywords
Abstract
One of the most common complications of COVID-19 is acute kidney injury (AKI). The frequency of AKI, according to various authors, varies widely and requires further study. Data on the prevalence of severe AKI, including those with renal replacement therapy (RRT), among patients with COVID-19 in the Uzbek population are limited [6]. Because AKI increases patient care costs, epidemiological data are essential for healthcare planning [7].
Data on the prevalence of various AKI phenotypes, their clinical features, the predictive role of changes in urine sediment, proteinuria, and markers of kidney damage in patients with COVID-19 in the Uzbek population are not available. In retrospective foreign studies, most patients with AKI were admitted with already impaired renal function [8, 9]. However, the prognostic role and predictors of the development of various AKI phenotypes remain unclear to date. The study of the predictive role of changes in urine sediment, proteinuria and biomarkers in the development of AKI and mortality in real clinical practice can become the basis for the development of an improved algorithm for managing patients with COVID-19: stratification of patients by risk of developing AKI, identification of high-risk groups